SI2880167T1 - Postopki in sestavki za in vivo indukcijo tvorbe celic beta trebušne slinavke - Google Patents

Postopki in sestavki za in vivo indukcijo tvorbe celic beta trebušne slinavke

Info

Publication number
SI2880167T1
SI2880167T1 SI201331101T SI201331101T SI2880167T1 SI 2880167 T1 SI2880167 T1 SI 2880167T1 SI 201331101 T SI201331101 T SI 201331101T SI 201331101 T SI201331101 T SI 201331101T SI 2880167 T1 SI2880167 T1 SI 2880167T1
Authority
SI
Slovenia
Prior art keywords
compositions
methods
beta cell
pancreatic beta
cell formation
Prior art date
Application number
SI201331101T
Other languages
English (en)
Inventor
Bruno Doiron
Ralph A. Defronzo
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of SI2880167T1 publication Critical patent/SI2880167T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01002—Glucokinase (2.7.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SI201331101T 2012-07-31 2013-07-31 Postopki in sestavki za in vivo indukcijo tvorbe celic beta trebušne slinavke SI2880167T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678077P 2012-07-31 2012-07-31
EP13824780.4A EP2880167B1 (en) 2012-07-31 2013-07-31 Methods and compositions for in vivo induction of pancreatic beta cell formation
PCT/US2013/052820 WO2014022455A1 (en) 2012-07-31 2013-07-31 Methods and compositions for in vivo induction of pancreatic beta cell formation

Publications (1)

Publication Number Publication Date
SI2880167T1 true SI2880167T1 (sl) 2018-12-31

Family

ID=50028488

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331101T SI2880167T1 (sl) 2012-07-31 2013-07-31 Postopki in sestavki za in vivo indukcijo tvorbe celic beta trebušne slinavke

Country Status (18)

Country Link
US (3) US9649344B2 (sl)
EP (1) EP2880167B1 (sl)
JP (2) JP6371765B2 (sl)
KR (1) KR102100093B1 (sl)
CN (1) CN104736711B (sl)
BR (1) BR112015002295B1 (sl)
CA (2) CA2880691C (sl)
CY (1) CY1120800T1 (sl)
DK (1) DK2880167T3 (sl)
ES (1) ES2679394T3 (sl)
HR (1) HRP20181124T1 (sl)
HU (1) HUE039520T2 (sl)
LT (1) LT2880167T (sl)
MX (1) MX360824B (sl)
PL (1) PL2880167T3 (sl)
PT (1) PT2880167T (sl)
SI (1) SI2880167T1 (sl)
WO (1) WO2014022455A1 (sl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004697A2 (en) 2006-04-07 2008-12-24 The Procter & Gamble Company Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
DK2451279T3 (da) 2009-07-06 2019-05-20 Aerpio Therapeutics Inc Benzosulfonamid derivater forbindelser deraf og deres brug til at forhindre metastaser af cancerceller
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
BR112015002295B1 (pt) * 2012-07-31 2022-02-01 The Board Of Regents Of The University Of Texas System Método para induzir a formação de célula beta in vitro
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
CN113713101B (zh) 2015-09-23 2023-07-28 视点制药公司 用tie-2的激活剂治疗眼内压的方法
WO2023039164A2 (en) * 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
WO2023225603A2 (en) * 2022-05-20 2023-11-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Insulin promoter for gene therapy for type 2 diabetes mellitus

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5383848A (en) * 1990-04-12 1995-01-24 Gensia, Inc. Iontophoretic administration of drugs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6261840B1 (en) * 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
JP2003189875A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 膵β細胞関連転写因子の遺伝子導入によるインスリン産生細胞の形成誘導
DE60328671D1 (de) 2002-03-26 2009-09-17 Banyu Pharma Co Ltd Neue aminobenzamidderivate
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
GB0227813D0 (en) * 2002-11-29 2003-01-08 Astrazeneca Ab Chemical compounds
EP1911235A1 (en) 2005-07-20 2008-04-16 Nxp B.V. Method and synchronizer for fine ofdm symbol synchronization and method/receiver for the reception of ofdm symbols
CA2557635C (en) 2005-08-31 2014-10-28 Lifescan, Inc. Methods to promote cell differentiation
EP1966152A2 (en) 2005-12-20 2008-09-10 Takeda Pharmaceutical Company Limited Glucokinase activators
CA2648852C (en) 2006-04-20 2012-12-11 Pfizer Products Inc. Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US9683215B2 (en) * 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
SG173182A1 (en) * 2009-02-03 2011-09-29 Hoffmann La Roche Compositions and methods for inhibiting expression of ptp1b genes
WO2012046084A2 (en) * 2010-10-08 2012-04-12 Mina Therapeutics Limited Short rna molecules
BR112015002295B1 (pt) * 2012-07-31 2022-02-01 The Board Of Regents Of The University Of Texas System Método para induzir a formação de célula beta in vitro

Also Published As

Publication number Publication date
MX2015001448A (es) 2015-07-14
KR102100093B1 (ko) 2020-05-15
KR20150038531A (ko) 2015-04-08
JP6666961B2 (ja) 2020-03-18
JP2015526432A (ja) 2015-09-10
EP2880167B1 (en) 2018-04-18
EP2880167A1 (en) 2015-06-10
CA2880691A1 (en) 2014-02-06
EP2880167A4 (en) 2016-03-30
PT2880167T (pt) 2018-07-23
US20170312318A1 (en) 2017-11-02
BR112015002295A2 (pt) 2018-05-08
LT2880167T (lt) 2018-10-25
CA3012929A1 (en) 2014-02-06
ES2679394T3 (es) 2018-08-27
JP2018172430A (ja) 2018-11-08
BR112015002295B1 (pt) 2022-02-01
US10293002B2 (en) 2019-05-21
MX360824B (es) 2018-11-15
US10980841B2 (en) 2021-04-20
US20150190432A1 (en) 2015-07-09
CN104736711B (zh) 2017-09-08
DK2880167T3 (en) 2018-07-30
CA3012929C (en) 2023-01-17
CN104736711A (zh) 2015-06-24
CY1120800T1 (el) 2019-12-11
US9649344B2 (en) 2017-05-16
CA2880691C (en) 2018-09-04
JP6371765B2 (ja) 2018-08-08
HUE039520T2 (hu) 2019-01-28
US20190307809A1 (en) 2019-10-10
HRP20181124T1 (hr) 2018-11-02
PL2880167T3 (pl) 2018-12-31
WO2014022455A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
HRP20181124T1 (hr) Postupci i pripravci za in vivo indukciju nastajanja beta stanica gušterače
HK1204330A1 (en) Factor viii compositions and methods of making and using same viii
HK1212594A1 (zh) 用於增强能量代謝的組合物和方法
EP2895559A4 (en) BITUMEN COMPOSITIONS AND METHODS OF MAKING
GB201216796D0 (en) In vitro pancreatic differentiation
IL230237B (en) Fat Cell Compounds and Methods
GB2503842B (en) Composition and method of manufacture
GB201200458D0 (en) Methods of preparing cells and compositions
IL266965B (en) Preparations containing pancreatic progenitor cells that are not multipurpose, and methods for their preparation
EP2838633A4 (en) DEMULATORY COMPOSITION AND METHOD FOR USE THEREOF
HK1205185A1 (en) Methods and composition related to brown adipose-like cells
EP2868747A4 (en) APTAMER FOR PERIOSTIN AND ANTICREACAST PREPARATION THEREOF
HK1254904B (zh) 用於改變xlhed表型的組合物和方法
HRP20181292T1 (hr) Vatrostalna mješavina i postupak njezine ugradnje
ZA201406909B (en) Modified agave food and method of making same
EP2718427A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF GLIOBLASTOMES